专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06306438B1 Stabilized sustained release tramadol formulations 失效
标题翻译：稳定缓释曲马多配方
公开(公告)号：US06306438B1
公开(公告)日：2001-10-23
申请号：US09109615
申请日：1998-07-02
申请人： Benjamin Oshlack , Hua-Pin Huang , Mark Chasin , Paul Goldenheim
发明人： Benjamin Oshlack , Hua-Pin Huang , Mark Chasin , Paul Goldenheim
IPC分类号： A61K922
CPC分类号： A61K9/2054 , A61K9/2013 , A61K9/2095
摘要： A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened during the preparation of the matrix, is cured at a temperature from about 35° C. to about 65° C. for a time period from about 4 to about 72 hours, such that the formulation, when subjected to in-vitro dissolution after exposure to accelerated storage conditions of at least one month at 40° C./75% RH, releases an amount of tramadol which does not vary at any given dissolution time point by more than about 20% of the total amount of tramadol released when compared to in-vitro dissolution conducted prior to subjecting the dosage form to the accelerated storage conditions.
摘要翻译：稳定的持续释放口服固体剂型，其包含分散在疏水性材料的基质中的有效量的曲马朵或其药学上可接受的盐，其包含在制备基质期间熔融或软化的蜡状物质，其在温度为约35℃至约65℃，时间为约4至约72小时，使得当暴露于至少一个月的加速储存条件后经受体外溶解时，该制剂 40℃/ 75％RH时，释放一定量的曲马多，与任何给定的溶解时间点相比，在与给药剂量之前进行的体外溶出相比，释放曲马多总量的大约20％形成加速存储条件。

2. 发明授权

US06645527B2 Stabilized sustained release tramadol formulations 有权
公开(公告)号：US06645527B2
公开(公告)日：2003-11-11
申请号：US10052844
申请日：2001-10-19
申请人： Benjamin Oshlack , Hua-Pin Huang , Mark Chasin , Paul Goldenheim
发明人： Benjamin Oshlack , Hua-Pin Huang , Mark Chasin , Paul Goldenheim
IPC分类号： A61K922
CPC分类号： A61K9/2054 , A61K9/2013 , A61K9/2095
摘要： A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened during the preparation of the matrix, is cured at a temperature from about 35° C. to about 65° C. for a time period from about 4 to about 72 hours, such that the formulation, when subjected to in-vitro dissolution after exposure to accelerated storage conditions of at least one month at 40° C./75% RH, releases an amount of tramadol which does not vary at any given dissolution time point by more than about 20% of the total amount of tramadol released when compared to in-vitro dissolution conducted prior to subjecting the dosage form to the accelerated storage conditions.

3. 发明申请

US20100172974A1 MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS 审中-公开
公开(公告)号：US20100172974A1
公开(公告)日：2010-07-08
申请号：US12722974
申请日：2010-03-12
申请人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
发明人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
IPC分类号： A61K9/48 , A61K9/22 , A61K9/14 , A61K31/135 , A61K31/451 , A61K31/439 , A61K31/454 , A61K31/4355 , A61K31/5377 , A61K31/137 , A61K31/167 , A61K31/381 , A61K31/4453 , A61K31/55 , A61K31/4184 , A61K31/4468 , A61K31/24 , A61P29/00
CPC分类号： A61K9/1635 , A61K9/145 , A61K9/1617 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2095 , B29B9/06 , Y10S514/951 , Y10S514/962
摘要： Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.
摘要翻译：公开了包含通过熔融挤出技术生产的多个多颗粒的生物可用持续释放口服阿片类镇痛剂型。

4. 发明授权

US5965161A Extruded multi-particulates 失效
标题翻译：挤出多颗粒
公开(公告)号：US5965161A
公开(公告)日：1999-10-12
申请号：US334209
申请日：1994-11-04
申请人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
发明人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
IPC分类号： A61K20060101 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/26 , A61K9/52 , A61K31/135 , A61K31/485 , A61K47/00 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38 , A61K47/44 , A61K47/46
CPC分类号： A61K9/1635 , A61K9/1617 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2095 , A61K9/145 , Y10S514/951 , Y10S514/962
摘要： A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.
摘要翻译：公开了包含多个熔融挤出颗粒的单位剂量持续释放口服剂型，每个主要由治疗活性剂，一种或多种阻滞剂和任选的水不溶性粘合剂组成。颗粒具有约0.1至约12mm的长度，并且可以具有不同的直径，并且每个单位剂量在至少约8小时内提供治疗活性剂的释放。还公开了制备单位剂量的方法以及挤出方法和治疗方法。

5. 发明授权

US06706281B2 Melt-extrusion multiparticulates 失效
标题翻译：熔融挤出多颗粒
公开(公告)号：US06706281B2
公开(公告)日：2004-03-16
申请号：US10038867
申请日：2002-01-02
申请人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
发明人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
IPC分类号： A61K916
CPC分类号： A61K9/1635 , A61K9/145 , A61K9/1617 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2095 , Y10S514/951 , Y10S514/962
摘要： A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.
摘要翻译：公开了包含多个熔融挤出颗粒的单位剂量持续释放口服剂型，每个主要由治疗活性剂，一种或多种阻滞剂和任选的水不溶性粘合剂组成。颗粒具有约0.1至约12mm的长度，并且可以具有不同的直径，并且每个单位剂量在至少约8小时内提供治疗活性剂的释放。还公开了制备单位剂量的方法以及挤出方法和治疗方法。

6. 发明授权

US5958452A Extruded orally administrable opioid formulations 失效
标题翻译：挤压口服阿片制剂
公开(公告)号：US5958452A
公开(公告)日：1999-09-28
申请号：US833948
申请日：1997-04-10
申请人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
发明人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
IPC分类号： A61K20060101 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/26 , A61K9/52 , A61K31/135 , A61K31/485 , A61K47/00 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/38 , A61K47/44 , A61K47/46
CPC分类号： A61K9/1635 , A61K9/1617 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2095 , A61K9/145 , Y10S514/951 , Y10S514/962
摘要： Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.
摘要翻译：公开了包含通过熔融挤出技术生产的多个多颗粒的生物可用持续释放口服阿片类镇痛剂型。

7. 发明授权

US06261599B1 Melt-extruded orally administrable opioid formulations 有权
标题翻译：熔融挤压口服阿片制剂
公开(公告)号：US06261599B1
公开(公告)日：2001-07-17
申请号：US09360056
申请日：1999-07-23
申请人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang , David Sackler
发明人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang , David Sackler
IPC分类号： A61K922
CPC分类号： A61K9/1635 , A61K9/145 , A61K9/1617 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2095 , Y10S514/951 , Y10S514/962
摘要： Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques disclosed.
摘要翻译：生物可利用的持续释放的口服阿片类镇痛剂型，包括通过熔体挤出技术生产的多种多颗粒。

8. 发明授权

US09149436B2 Pharmaceutical product comprising a sequestered agent 有权
标题翻译：包含螯合剂的药物产品
公开(公告)号：US09149436B2
公开(公告)日：2015-10-06
申请号：US10827623
申请日：2004-04-19
申请人： Benjamin Oshlack , Glenn Van Buskirk , Mark Chasin , Hua-Pin Huang , Vijay Vashi
发明人： Benjamin Oshlack , Glenn Van Buskirk , Mark Chasin , Hua-Pin Huang , Vijay Vashi
IPC分类号： A61K9/20 , A61K9/14 , A61K31/485 , A61K45/06 , A61K9/16 , A61K9/50
CPC分类号： A61K9/2081 , A61K9/1617 , A61K9/1635 , A61K9/282 , A61K9/2826 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K9/5084 , A61K9/5123 , A61K9/5138 , A61K31/485 , A61K45/06 , A61K2300/00
摘要： Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.
摘要翻译：在某些实施方案中公开了包含多个包含不利剂或拮抗剂的挤出颗粒和围绕颗粒设置的层的剂型。

9. 发明授权

US06335033B2 Melt-extrusion multiparticulates 有权
标题翻译：熔融挤出多颗粒
公开(公告)号：US06335033B2
公开(公告)日：2002-01-01
申请号：US09358828
申请日：1999-07-22
申请人： Benjamin Oshlack , Hua-Pin Huang , Mark Chasin
发明人： Benjamin Oshlack , Hua-Pin Huang , Mark Chasin
IPC分类号： A61K916
CPC分类号： A61K9/1635 , A61K9/145 , A61K9/1617 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2095 , Y10S514/951 , Y10S514/962
摘要： A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.
摘要翻译：公开了包含多个熔融挤出颗粒的单位剂量持续释放口服剂型，每个主要由治疗活性剂，一种或多种阻滞剂和任选的水不溶性粘合剂组成。颗粒具有约0.1至约12mm的长度，并且可以具有不同的直径，并且每个单位剂量在至少约8小时内提供治疗活性剂的释放。还公开了制备单位剂量的方法以及挤出方法和治疗方法。

10. 发明授权

US07510727B2 Melt-extrusion multiparticulates 失效
公开(公告)号：US07510727B2
公开(公告)日：2009-03-31
申请号：US10745950
申请日：2003-12-23
申请人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
发明人： Benjamin Oshlack , Mark Chasin , Hua-Pin Huang
IPC分类号： A61K9/16
CPC分类号： A61K9/1635 , A61K9/145 , A61K9/1617 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2095 , Y10S514/951 , Y10S514/962
摘要： A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式